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Abstract
Background: The clinical significance of non-alcoholic fatty pancreatic disease (NAFPD) or fatty pancreas is largely
unknown. It is often an incidental finding on abdominal ultrasound, which is not explored further, especially its
association with metabolic condition and the risk of pancreatic malignancy. The aim of this study is to evaluate the
presence of NAFPD and its associated risk factors among adult medical check-up patients.
Method: A large cross-sectional study was done among adult medical check-up patients underwent abdominal
ultrasound between January and December 2013 in Medistra Hospital, Jakarta. Data was obtained from the
patients’ medical record and include demographic data, blood pressures, fasting blood glucose level, and lipid
profile. The presence of fatty pancreas was diagnosed by ultrasound. Bivariate and multivariate analyses were
done to find associated risk factors for NAFPD. Statistical analysis was done using SPSS version 17.
Results: A total of 1054 cases were included in this study; pancreas cannot be visualized in 153 cases and
were excluded from the analysis. Fatty pancreas was present in 315 (35.0 %) patients. Bivariate analyses found
associations among fatty pancreas and several risk factors such as gender, age, systolic and diastolic blood
pressures, body mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cholesterol levels.
Conclusion: Fatty pancreas is a common finding during medical check-up with a prevalence of 35 %. Fatty pancreas
has significant association with metabolic factors and it might have an important role in risk of malignancy.
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Background
High energy intake in human may lead to excessive fat
which could be accumulated in visceral organs that are
unusual for adipose tissue storage, the so-called ectopic
fat [1]. Fatty pancreas or nonalcoholic fatty pancreatic
disease (NAFPD) is an excessive fat infiltration of the
pancreas due to obesity in the absence of significant al-
cohol intake [2]. Fatty pancreas is a common ultrasound
finding which has increased echogenicity when com-
pared to the normal pancreas [3].
On the contrary to the nonalcoholic fatty liver disease
(NAFLD), the potential systemic and local consequences
of excessive fat accumulation in the pancreas have not
been well established. Fatty infiltration in the pancreas has
been showed to correlate with the metabolic risk factors
and may represent a meaningful manifestation of meta-
bolic syndrome., [4, 5] Epidemiology study also suggests
that obesity is a risk factor for pancreatic cancer [6]. Based
on a recent study, fatty infiltration in the pancreas may
increase the risk of pancreatic ductal adenocarcinoma be-
yond the effect of obesity alone [7]. The problem with
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the organ location needs the more accurate imaging
diagnostic procedures, such as abdominal MRI or even
Endoscopic Ultrasound (EUS). The fat content of the
pancreas also can be estimated by 3D two point Dixon
techniques. However, in population or medical checkup
settings, it would be unpractical and also costly to
examine the pancreas [8–10].
Since the clinical implication of fatty pancreas is still a
mater of debate, especially in countries where alcohol
consumption is not an issue, therefore, this study was
aimed to evaluate the presence of fatty pancreas and
estabslihed its associated risk factors.
Method
Study design and subject
The study design was an analytical cross-sectional study
among medical check-up patients in Medistra Hospital
which has been approved from the Medistra hospital’s
local ethics committee between January and December
2013. Inclusion criteria was adult patients aged more
than 18 years, no serious illness at the time of examin-
ation, having routine laboratory check-up for liver func-
tion test, fasting plasma glucose (FPG) levels, and lipid
profile, and underwent abdominal ultrasound assess-
ment. None of the patients had a history of significant
alcohol drinking (<20 g/day). Patients were excluded
from analyses if the pancreas was not visualized on
ultrasound or laboratory data was incomplete. Risk fac-
tors of NAFPD tested were gender, age group, history
of diabetes, body mass index (BMI), systolic and dia-
stolic blood pressures (BP), FPG, triglycerides, total
cholesterol, low-density lipoprotein (LDL)-cholesterol,
and high-density lipoprotein (HDL)-cholesterol levels.
Diabetes mellitus (DM) is diagnosed based on clear his-
tory from patient’s interview and the blood glucose
database. The metabolic data parameters were collected
as the parameters which become our hospital medical
check-up standard examination. The minimum sample
size for estimating one population proportion at an an-
ticipated proportion of 50 %, 99 % level of confidence
and 5 % margin of error was 664 patients.
Diagnosis of fatty pancreas
Fatty pancreas or pancreas lipomatosis was diagnosed
using abdominal ultrasound technique performed by
one experienced radiologist in the hospital using a high-
resolution ultrasound machine equipped with a 3.5 MHz
convex-array probe (LOGIC S7, GE System, US). The
radiologist who performed the ultrasound examinations
was blinded to the laboratory data; the results were
evaluated by another experienced radiologist to ensure
unbiased evaluation. Pancreatic echogenicity was com-
pared to the liver echogenicity at the same depth on a
longitudinal scan taken near the abdominal midline [11].
If the liver also showed increased echogenicity, compari-
son was also made with the renal cortex. Diagnosis of pan-
creas lipomatosis was established if there is increased
echogenicity of the pancreas over the liver or renal cortex.
Laboratory tests
All subjects underwent laboratory tests for standard med-
ical check-up consisting of complete peripheral blood test,
liver function test, fasting plasma glucose and lipid profil-
ing. These tests were performed after an overnight fast for
a minimum of 10 h.
Statistical analyses
Characteristics of the study subjects were presented de-
scriptively. Bivariate analyses between the presence of
NAFPD and risk factors were performed using the Chi-
square test. A p value of less than 0.05 was considered
significant. Multivariate logistic regression was used to
find independent risk factors for NAFPD. Statistical
analysis was done using SPSS version 17.0.
Results
Characteristics of the study subjects
There were 1054 cases enrolled in the analysis; 720
(68.3 %) of them were men. The mean age was 43.1 ±
12.19 years old. Other characteristics were summarized
in Table 1. Pancreas was non-visualized in 153 (14.5 %)
cases. In the remaining 901 cases, fatty pancreas was
found in 315 (35 %) patients.
Associations among metabolic risk factors and fatty liver
The presence of fatty pancreas were significantly associ-
ated with male gender, age >35 years, higher systolic and
diastolic blood pressures, fasting blood glucose >100 mg/
Table 1 Characteristics of the study subject (N = 1054)
Characteristic Mean (SD) N %
Male gender 720 68.3
Age (years) 43.1 ± 12.19
Age >35 years old 723 68.6
Body mass index (kg/m2) 24.9 ± 3.96
Systolic blood pressure (mmHg) 120 ± 37.2
Diastolic blood pressure (mmHg) 75 ± 9.9
Fasting plasma glucose (mg/dL) 96.7 ± 24.69
Triglyceride levels (mg/dL) 127.1 ± 89.15
Total cholesterol levels (mg/dL) 205.4 ± 59.0
LDL-cholesterol 133.2 ± 35.29
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dL, triglycerides, total and LDL-cholesterol, and lower
HDL cholesterol levels (Table 2).
Association between fatty pancreas and fatty liver
Fatty liver was present in 538 (51.0 %) of the total study
subjects. Among 901 patients with visualized pancreas,
fatty pancreas coexisted with fatty liver in 232 (25.7 %)
patients; both were absent in 381 (42.3 %) patients. In
addition, fatty pancreas with normal liver was found in
83 patients (16.0 %) and fatty liver with normal pancreas
was seen in 205 (39.4 %) patients. There was a signifi-
cant association between fatty pancreas and fatty liver
(OR: 5.195; 95 %CI: 3.838-7.032; p < 0.001).
When the 381 patients with neither fatty liver nor fatty
pancreas were excluded, fatty pancreas coexisted with
fatty liver in 232 patients (44.6 %). This number can be
brokendown further, revealing that fatty pancreas was
found in 53.1 % of patients with fatty liver whereas fatty
liver can be found in 73.7 % of patients with fatty pan-
creas (Fig. 1).
Association between fatty pancreas and diabetes mellitus
Type 2 diabetes mellitus was present in 62 (6.9 %) of the
study subects and fatty pancreas was detected in 31 (50 %)
of them. Statistically, diabetes has significant associated
with fatty pancreas (OR 1.953; 95 % CI: 1.164–3.280;
p < 0.001). However, when entered into the multivari-
ate analyses; diabetes failed to show a significant asso-
ciation, suggesting that it was a confounding factor
rather than an independent risk factor.
Discussion
Characteristics of the study subjects
With a detection rate of 35 %, our study showed that the
prevalence of nonalcoholic fatty pancreas is high among
adult patients underwent routine medical check-up. A
recent study involving 8097 subjects underwent health
check-up in Taiwan found only 16 % prevalence of fatty
pancreas detected by abdominal ultrasound [12]. On the
contrary, a Korean study found that 67.9 % of 293 sub-
jects visiting an obesity clinic had fatty pancreas detected
by abdominal ultrasound. Larger sample size allows more
valid generalization into the general population; therefore,
the estimated prevalence of fatty pancreas in the real com-
munity may be best represented by the Taiwanese study.
The subjects of our study might give an over-estimate re-
sult because most of our hospital’s medical check-up sub-
jects came from high social economic groups. Our study
may also not represent the true Indonesian population
since the patients were recruited from a referral private
hospital. However, the high prevalence of NAFPD has
given a new insight in patient’s follow up and screening as
the risk of malignancy might also be increasing. A more
accurate estimation might be shown by a recent study
among 685 Hong Kong Chinese healthy volunteers; the
prevalence of fatty pancreas detected by fat-water mag-
netic resonance imaging was 16.1 % [13].
Association between fatty pancreeas and metabolic risk
factors
Our results showed significant association between fatty
pancreas and metabolic risk factors (Table 2). Table 3
showed independent risk factors to predict fatty pan-
creas. These results were consistent with previous epi-
demiological report in Hong Kong Chinese population
[10]. The OR of DM and other variables mostly around
the value of 2.0; therefore although systolic BP have
higher OR, the difference with DM or triglycerides can
be considered not too wide. However, the number of
subjects with DM is relatively small compared to other
variables. It could affect the statistical calculation of OR
and may explain the slight difference with systolic BP.
Table 2 Associations among risk factors and the presence of fatty pancreas (n = 901)
Risk Factor Fatty pancreas Odds ratio p value
Yes (n = 315) No (n = 586) (95 % CI) (χ2)
Male sex (n = 574) 228 (72.4 %) 346 (59.0 %) 1.818 (1.351–2.446) <0.001
Age > 35 years (n = 612) 268 (85.1 %) 344 (58.7 %) 4.011 (2.824–5.697) <0.001
Systolic BP ≥ 130 mmHg (n = 201) 99 (31.4 %) 102 (17.4 %) 2.175 (1.580–2.994) <0.001
Diastolic BP ≥ 85 mmHg (n = 111) 54 (17.1 %) 57 (9.7 %) 1.920 (1.286–2.866) 0.001
Body mass index≥ 25 kg/m2 (n = 390) 206 (65.4 %) 184 (31.4 %) 4.129 (3.088–5.520) <0.001
Type 2 diabetes mellitus (n = 62) 31 (9.8 %) 31 (5.3 %) 1.954 (1.164–3.280) 0.010
FPG≥ 100 mg/dL (n = 187) 99 (31.4 %) 88 (15.0 %) 2.594 (1.867–3.603) <0.001
Triglycerides ≥ 150 mg/dL (n = 226) 105 (33.3 %) 121 (20.6 %) 1.921 (1.412–2.615) <0.001
Total cholesterol≥ 200 mg/dL (n = 491) 203 (64.4 %) 288 (49.1 %) 1.875 (1.415–2.486) <0.001
LDL-C≥ 100 mg/dL (n = 742) 275 (87.3 %) 467 (79.7 %) 1.752 (1.189–2.582) 0.004
HDL-C < 40 (M) or < 50 (F) mg/dL (n = 194) 86 (27.3 %) 108 (18.4 %) 1.662 (1.202–2.298) 0.002
BMI body mass index, FPG fasting plasma glucose, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
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From the statistical point of view, clinical value of an
OR occurs when it is more than 1.5. Compared to age
or BMI (which have OR >4.0), the ORs of DM and sys-
tolic BP are much weaker, it’s also the same with other
variables with OR value less than 2.0. From the meta-
bolic point of view, DM is considered as part of meta-
bolic syndrome with could confound other variables
within the metabolic markers group (such as cholesterol
or TG). On the other hand, blood pressure is a
hemodynamic marker. High blood pressure in metabolic
syndrome is a consequence of insulin resistance with
various underlying mechanisms [14]. Therefore, higher
OR of systolic BP might reflect that is more important
as risk factor than DM or other lipid parameters.
Association between fatty pancreas and fatty liver
Fatty liver was reported as a predictor of “hyperechogenic
pancreas” seen during endoscopic ultrasound [15]. A post-
mortem study collected from 80 cadavers found that total
pancreatic fat was a significant predictor of NAFLD, but
no correlation was found between pancreatic fat and
NAFLD activity score after corrected for body mass index
[16]. Our study showed significant correlation between
fatty pancreas and fatty liver, however whether with these
two entities might doubling the risk of malignancy is still
unknown.
Despite the presence of statistical association, the
pathophysiology underlying both conditions might be
coincidence rather than causative. Both fatty pancreas
and fatty liver are significantly associated with metabolic
risk factors due to excessive energy intake.
Association between fatty pancreas and diabetes mellitus
Based on our study, even though there is a significant as-
sociation between the presence of fatty pancreas and dia-
betes mellitus, however the association was not observed
in the multivariate analysis. Different result was reported
among 7464 subjects underwent physical check-up in
Taiwan. This might be due to the smaller size effect in the
subgroup analysis. The investigators did found an inde-
pendent association between fatty pancreas and diabetes
(OR: 1.379; 95 %CI: 1-047-1.816) [17]. However, this study
Table 3 Independent risk factors to predict fatty pancreas (N = 901)
Risk factor β SE (β) β/SE ORadj 95 % CI p value
Age > 35 years 1.077 0.191 5.639 2.936 2.020–4.267 <0.001
BMI≥ 25 kg/m2 1.261 0.154 8.188 3.529 2.607–4.775 <0.001
FPG≥ 100 mg/dL 0.531 0.183 2.902 1.701 1.189–2.434 0.004
Total cholesterol≥ 200 mg/dL 0.491 0.157 3.127 1.634 1.201–2.223 <0.001
Constant −2.423
BMI body mass index, FPG fasting plasma glucose
Fig. 1 Frequency of fatty pancreas in relation to the presence of fatty liver among patients with visualized pancreas
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was not designed to establish a direct causal relationship
between diabetes mellitus and fatty pancreas or vice versa
and should be interpreted as such. The complex factor in
insulin resistance pathway might play an important factor.
High free fatty acid (FFA) will induce the accumulation of
pancreatic fat and the fat deposition will disrupt the beta
cell function. The beta cell dysfunction results in unmet
relative insulin need to maintain optimal glycemic control
and in combination with insulin resistance at the periph-
ery synergistically contributes to the long-term hypergly-
cemia. This is an important pathway for the development
of diabetes mellitus. In return, the insulin resistance con-
dition where induced by FFA source in the pancreas might
induce the chronic inflammation stage where this can be-
come a malignancy risk [18]. With these findings, we
might also need to screen our diabetes patients for pan-
creatic malignancy risk.
This study has several limitations. First, the study was
designed as a cross-sectional study which cannot prove
causal link between fatty pancreas and the associated
factors. However, the large sample size in this study
could provide generalization to the larger population of
interest. Body mass index (BMI) as a risk for pancreatic
lipomatosis might be a confounding factor to detect the
presence of fatty pancreas. Second, the data about dia-
betes medication not being reported based on our MCU
standard examination record. But this study has given
the importance of metabolic factors associated with the
presence of NAFPD. Third, the need to differentiate be-
tween simple steatosis and steatosis with inflammation
in the pancreas has not been elucidated. The transab-
dominal ultrasound study might not be the best of
choice, but ultrasound is still a qualified technique in an
experienced hand, and also cheaper when compared to
MRI in the community setting. Further study with ethical
consideration will be needed to perform pancreas biopsy
using EUS study.
Conclusion
The prevalence of NAFPD in Indonesia is high and it is
strongly correlated with other metabolic conditions. The
clinical significance of routine fatty pancreas screening
needs to be included in our clinical practice. However, it
would need further investigation about the long standing
condition of fatty pancreas and the usefulness of pancre-
atic biopsy to see the possibility of disease progression.
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